Trial Profile

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab (Primary) ; Pembrolizumab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms MK-4280-003
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

28 Feb 2025 Planned End Date changed from 19 Oct 2028 to 16 Jan 2026.
28 Feb 2025 Planned primary completion date changed from 19 Oct 2028 to 16 Jan 2026.
24 Dec 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com